Suppr超能文献

晚期肺癌患者胸部手术活检进行肿瘤分子谱分析的结果和疗效。

Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer.

机构信息

Section of General Thoracic Surgery, University of California, Davis Medical Center, Sacramento, Calif; University of California, Davis Comprehensive Cancer Center, Sacramento, Calif.

University of California, Davis Comprehensive Cancer Center, Sacramento, Calif.

出版信息

J Thorac Cardiovasc Surg. 2014 Jul;148(1):36-40. doi: 10.1016/j.jtcvs.2014.03.014. Epub 2014 Mar 19.

Abstract

BACKGROUND

Molecular testing of patients with advanced non-small cell lung cancer for personalized therapy often is limited by insufficient specimen from nonsurgical biopsies. We measured the feasibility, patient safety, and clinical impact of thoracic surgical tumor biopsy in patients with stage IV non-small cell lung cancer.

METHODS

This is a single institution retrospective analysis. Patients with stage IV non-small cell lung cancer undergoing elective surgical tissue biopsy for molecular analysis were evaluated from March 2011 to November 2012. Perioperative specific variables were measured.

RESULTS

Twenty-five patients with known or suspected stage IV non-small cell lung cancer undergoing surgical biopsy were identified. All cases were discussed at a multidisciplinary thoracic oncology conference or a multidisciplinary thoracic oncology clinic. Preoperative histologies included adenocarcinoma in 20 patients (80.0%) and squamous cell carcinoma in 2 patients (8.0%). Surgical procedures consisted of video-assisted thoracic surgery wedge biopsy (16, 64%), video-assisted thoracic surgery pleural biopsy (4, 16.0%), mediastinoscopy (2, 8.0%), supraclavicular/cervical lymph node excisional biopsy (3, 12.0%), and rib/chest wall resection (2, 8.0%). There were no deaths and 5 postoperative complications (20.0%). Surgery identified potentially targetable molecular information in 19 of the total patients undergoing operation (76.0%) and changed the treatment strategy in 14 patients (56.0%); 10 of the total cohort (40.0%) were enrolled into therapeutic targeted clinical trials.

CONCLUSIONS

These data suggest that thoracic surgical biopsy can be safely performed in appropriately selected patients with stage IV non-small cell lung cancer and direct personalized therapy and enrollment into relevant clinical trials. Patients with advanced-stage non-small cell lung cancer should be discussed in a multidisciplinary setting to determine the need and strategy for thoracic surgical biopsy for molecular analysis.

摘要

背景

对晚期非小细胞肺癌患者进行个性化治疗的分子检测通常受到非手术活检标本不足的限制。我们测量了在 IV 期非小细胞肺癌患者中进行胸外科肿瘤活检的可行性、患者安全性和临床影响。

方法

这是一项单中心回顾性分析。对 2011 年 3 月至 2012 年 11 月期间因分子分析而接受选择性手术组织活检的 IV 期非小细胞肺癌患者进行了评估。测量了围手术期的具体变量。

结果

确定了 25 例已知或疑似 IV 期非小细胞肺癌患者接受手术活检。所有病例均在多学科胸肿瘤科会议或多学科胸肿瘤科诊所进行了讨论。术前组织学包括腺癌 20 例(80.0%)和鳞状细胞癌 2 例(8.0%)。手术程序包括电视辅助胸腔镜楔形活检(16 例,64.0%)、电视辅助胸腔镜胸膜活检(4 例,16.0%)、纵隔镜检查(2 例,8.0%)、锁骨/颈淋巴结切除术(3 例,12.0%)和肋骨/胸壁切除术(2 例,8.0%)。无死亡病例,术后并发症 5 例(20.0%)。在接受手术的 19 例患者中,手术确定了潜在的可靶向分子信息(76.0%),并改变了 14 例患者的治疗策略(56.0%);10 例患者(40.0%)入组了治疗性靶向临床试验。

结论

这些数据表明,在适当选择的 IV 期非小细胞肺癌患者中,胸外科活检可以安全进行,并可直接进行个性化治疗和入组相关临床试验。晚期非小细胞肺癌患者应在多学科环境中进行讨论,以确定是否需要进行胸外科活检以进行分子分析以及制定相应策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验